Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aeterna Zentaris (AEZS)

Aeterna Zentaris (AEZS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,250
  • Shares Outstanding, K 23,510
  • Annual Sales, $ 530 K
  • Annual Income, $ -6,040 K
  • 60-Month Beta 1.98
  • Price/Sales 19.18
  • Price/Cash Flow N/A
  • Price/Book 6.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/11/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3697 +17.93%
on 07/02/20
1.1300 -61.42%
on 06/11/20
-0.7040 (-61.75%)
since 06/10/20
3-Month
0.3697 +17.93%
on 07/02/20
1.2900 -66.20%
on 05/28/20
-0.2540 (-36.81%)
since 04/09/20
52-Week
0.3697 +17.93%
on 07/02/20
2.8349 -84.62%
on 07/12/19
-2.3040 (-84.09%)
since 07/10/19

Most Recent Stories

More News
AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of...

AEZS : 0.4360 (+0.46%)
AEZS.TO : 0.60 (+3.45%)
AETERNA ZENTARIS ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the pricing of...

AEZS : 0.4360 (+0.46%)
AEZS.TO : 0.60 (+3.45%)
AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered...

AEZS : 0.4360 (+0.46%)
AEZS.TO : 0.60 (+3.45%)
Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has regained...

AEZS : 0.4360 (+0.46%)
AEZS.TO : 0.60 (+3.45%)
Aeterna Zentaris Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company...

AEZS : 0.4360 (+0.46%)
AEZS.TO : 0.60 (+3.45%)
Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the...

AEZS : 0.4360 (+0.46%)
AEZS.TO : 0.60 (+3.45%)
Aeterna Zentaris Announces Virtual 2020 Annual Meeting of Shareholders

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced its...

AEZS : 0.4360 (+0.46%)
AEZS.TO : 0.60 (+3.45%)
Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results

- First quarter marked by positive results from AEZS-130-P01 ("Study P01"), of macimorelin, providing clinical framework to advance pediatric investigation plan ("PIP") for macimorelin as a growth hormone...

AEZS : 0.4360 (+0.46%)
AEZS.TO : 0.60 (+3.45%)
Could This Be the Medical Breakthrough for The Next Decade

, /PRNewswire/ -- A new medical development is sweeping the country. Some may see it as controversial - but the studies don't lie. It's effective. So effective, in fact, that the FDA has just fast-tracked...

SAGE : 42.92 (-2.70%)
SAVA : 3.34 (+8.99%)
APTO : 6.02 (-4.60%)
AEZS : 0.4360 (+0.46%)
CRHM : 2.18 (-0.91%)
Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna Zentaris" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced...

AEZS : 0.4360 (+0.46%)
AEZS.TO : 0.60 (+3.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AEZS with:

Business Summary

AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead...

See More

Key Turning Points

2nd Resistance Point 0.4699
1st Resistance Point 0.4530
Last Price 0.4360
1st Support Level 0.4201
2nd Support Level 0.4041

See More

52-Week High 2.8349
Fibonacci 61.8% 1.8932
Fibonacci 50% 1.6023
Fibonacci 38.2% 1.3114
Last Price 0.4360
52-Week Low 0.3697

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar